Determining When to Add Nonstatin Therapy A Quantitative Approach
ConclusionsAdding ezetimibe or PCSK9 monoclonal antibodies to maximally tolerated statin therapy may be cost effective in very high-risk and high-risk patients, depending on baseline LDL-C levels.
Source: Journal of the American College of Cardiology - Category: Cardiology Source Type: research
More News: Cardiology | Cardiovascular | Cholesterol | Heart | Statin Therapy | Study | Vytorin | Zetia